EARTH LIFE SCIENCES INC
CLTSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CLTS. That does not mean none is planned.
Get an email about CLTS's next catalysts
Track EARTH LIFE SCIENCES (CLTS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
Prostate Cancer
18F-Fluciclovine PET CT
Cancer of the Prostate
rhPSMA-7.3 (18F) Injection
Prostate Cancer
18F fluciclovine
Brain Metastases
Arm A: 177Lu rhPSMA-10.1
Prostate Cancer
18F-rhPSMA-7.3 (Posluma)
Prostate Cancer (Post Prostatectomy)
18F-fluciclovine PET Scan
Metastatic Castration-resistant Prostate Cancer
FACBC PET-CT
Prostate Cancer
Androgen Deprivation Therapy (ADT) +/- bicalutamide
Intermediate Risk Prostate Cancer
18F-Fluciclovine
Brain Metastases
Flotufolastat F18
Prostatic Neoplasms
Actinium (225Ac) rhPSMA-10.1
Metastatic Castration-resistant Prostate Cancer
Furosemide
Prostate Adenocarcinoma
Leuprolide
Prostate Cancer
[18F]FPyQCP
Colorectal Cancer
Prednisone
Prostate Adenocarcinoma
Lutetium (177Lu) rhPSMA-10.1 Injection
Prostate Cancer
[68Ga]BED003
Colorectal Cancer
Fluorine F 18 Flotufolastat
Prostate Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent | Phase 3 | Prostate Cancer | - | - |
18F-Fluciclovine PET CT | Phase 3 | Cancer of the Prostate | - | - |
rhPSMA-7.3 (18F) Injection | Phase 3 | Prostate Cancer | - | - |
18F fluciclovine | Phase 3 | Brain Metastases | - | - |
Arm A: 177Lu rhPSMA-10.1 | Phase 2 | Prostate Cancer | - | - |
18F-rhPSMA-7.3 (Posluma) | Phase 2 | Prostate Cancer (Post Prostatectomy) | - | - |
18F-fluciclovine PET Scan | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
FACBC PET-CT | Phase 2 | Prostate Cancer | - | - |
Androgen Deprivation Therapy (ADT) +/- bicalutamide | Phase 2 | Intermediate Risk Prostate Cancer | - | - |
18F-Fluciclovine | Phase 2 | Brain Metastases | - | - |
Flotufolastat F18 | Phase 2 | Prostatic Neoplasms | - | - |
Actinium (225Ac) rhPSMA-10.1 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Furosemide | Phase 2 | Prostate Adenocarcinoma | - | - |
Leuprolide | Phase 2 | Prostate Cancer | - | - |
[18F]FPyQCP | Phase 2 | Colorectal Cancer | - | - |
Prednisone | Phase 2 | Prostate Adenocarcinoma | - | - |
Lutetium (177Lu) rhPSMA-10.1 Injection | Phase 2 | Prostate Cancer | - | - |
[68Ga]BED003 | Phase 2 | Colorectal Cancer | - | - |
Fluorine F 18 Flotufolastat | Phase 2 | Prostate Carcinoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in EARTH LIFE SCIENCES INC's drug pipeline?→
CatalystAlert tracks 19 drug candidates in EARTH LIFE SCIENCES INC's (CLTS) pipeline across Phase 3, Phase 2. Its lead program is 18F fluciclovine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EARTH LIFE SCIENCES INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for EARTH LIFE SCIENCES INC (CLTS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CLTS biotech catalysts?→
Add CLTS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EARTH LIFE SCIENCES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.